Former Miss Ireland Holly Carpenter revealed she chose sobriety on her wedding day, citing concerns that medications like Ozempic (semaglutide) perpetuate harmful beauty standards in the modelling industry by promoting extreme thinness as an ideal. Her comments highlight growing scrutiny over off-label use of glucagon-like peptide-1 (GLP-1) receptor agonists for cosmetic weight loss, particularly among individuals without clinical obesity, raising questions about long-term safety, equitable access for patients with diabetes or obesity, and the influence of celebrity culture on pharmaceutical trends.
How GLP-1 Receptor Agonists Like Ozempic Work in the Body
Ozempic contains semaglutide, a synthetic version of the human glucagon-like peptide-1 (GLP-1) hormone. GLP-1 is naturally released after eating and works by binding to receptors in the pancreas, brain, and gastrointestinal tract. This binding stimulates insulin secretion when blood sugar is high, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce hunger and increase satiety. These combined effects lower blood glucose and promote weight loss, which is why semaglutide is approved for type 2 diabetes management and, at higher doses (as Wegovy), for chronic weight management in adults with obesity or overweight with comorbidities.
In Plain English: The Clinical Takeaway
- GLP-1 medications like Ozempic are scientifically proven to help control blood sugar and support weight loss in people with type 2 diabetes or obesity when used as prescribed.
- Using these drugs solely for cosmetic weight loss without medical need carries risks, including gastrointestinal side effects, potential pancreatitis, and unknown long-term effects.
- Access to these medications should be prioritized for patients with clinical indications, as off-label cosmetic use can worsen shortages and exacerbate health inequities.
Epidemiological Context and Regulatory Landscape in Europe and Beyond
In Ireland, where Carpenter is based, the Health Service Executive (HSE) reports that over 60% of adults are overweight or obese, yet access to GLP-1 therapies remains restricted due to cost and prescribing guidelines limiting use to patients with BMI ≥30 or ≥27 with comorbidities. Across the European Union, the European Medicines Agency (EMA) has approved semaglutide (Ozempic and Wegovy) for diabetes and obesity treatment, but explicitly warns against use for cosmetic purposes. In contrast, the U.S. Food and Drug Administration (FDA) has issued similar warnings, noting a surge in off-label prescriptions driven by social media trends, which has contributed to intermittent shortages affecting diabetic patients.
According to a 2024 study published in The Lancet Diabetes & Endocrinology, off-label use of GLP-1 agonists for weight loss in individuals without obesity increased by 300% in high-income countries between 2020 and 2023, with the highest prevalence among young adults in appearance-focused professions such as modelling, entertainment, and social media influencing. This trend raises ethical concerns about medicalizing normal body variation and diverting resources from those with clinical need.
Funding Sources and Research Integrity
The foundational clinical trials for semaglutide in obesity (STEP program) were primarily funded by Novo Nordisk, the pharmaceutical company that develops and markets the drug. While industry funding is common in drug development, independent analyses have confirmed the efficacy and safety findings. For example, a 2023 Cochrane Review concluded that semaglutide leads to clinically meaningful weight reduction (average 10-15% of body weight over 68 weeks) compared to placebo, with nausea, vomiting, and diarrhea being the most common adverse events. Importantly, the review noted that long-term data beyond two years remain limited, underscoring the need for continued surveillance.
Expert Perspectives on Medical Ethics and Public Health Impact
“The rising demand for GLP-1 agonists for lifestyle weight loss, particularly in industries that equate thinness with success, risks transforming a vital medical therapy into a cosmetic commodity. We must safeguard access for patients who rely on these drugs to manage life-threatening conditions.”
“Regulatory agencies are monitoring off-label use closely, but the real solution lies in addressing societal pressures that drive unhealthy weight ideals, not in restricting medications that help those with genuine medical need.”
Comparative Efficacy and Safety of GLP-1 Agonists in Clinical Trials
| Study | Population | Intervention | Duration | Mean Weight Loss | Common Side Effects (≥10%) |
|---|---|---|---|---|---|
| STEP 1 (NEJM, 2021) | Adults with obesity or overweight (N=1,961) | Semaglutide 2.4 mg weekly | 68 weeks | 14.9% | Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%) |
| SUSTAIN 6 (NEJM, 2016) | Adults with type 2 diabetes (N=3,297) | Semaglutide 0.5 or 1.0 mg weekly | 104 weeks | 4.7% (vs 0.5% placebo) | Nausea (20%), diarrhea (16%), vomiting (9%), decreased appetite (14%) |
| PIONEER 6 (Lancet, 2019) | Adults with type 2 diabetes and CVD risk (N=3,183) | Oral semaglutide 14 mg daily | Up to 76 weeks | 3.2% weight change | Nausea (15%), decreased appetite (12%), diarrhea (10%) |
Contraindications &. When to Consult a Doctor
GLP-1 receptor agonists like Ozempic are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), due to observed thyroid C-cell tumors in rodent studies. They should also be avoided in patients with a history of pancreatitis. Caution is advised in those with severe gastrointestinal disease, such as gastroparesis, as delayed gastric emptying may worsen symptoms.
Patients should seek immediate medical attention if they experience persistent severe abdominal pain (possible pancreatitis), vomiting that prevents fluid intake, signs of allergic reaction (swelling, difficulty breathing), or symptoms of hypoglycemia (especially when combined with insulin or sulfonylureas). Routine monitoring by a healthcare provider is essential to assess efficacy, tolerability, and emerging safety signals.
The Takeaway: Balancing Innovation with Responsibility
Holly Carpenter’s decision to abstain from alcohol on her wedding day reflects a personal commitment to authenticity in an industry often driven by image. Her critique of Ozempic’s role in reinforcing unrealistic thinness ideals opens a necessary conversation about the ethical use of powerful metabolic medications. While GLP-1 agonists represent a transformative advance for patients with diabetes and obesity, their misuse for cosmetic purposes threatens to undermine public trust, exacerbate health disparities, and distract from the societal work needed to challenge harmful beauty norms. Moving forward, clinicians, regulators, and media must collaborate to ensure these therapies are used responsibly—guided by evidence, not aesthetics.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834-1844.
- Ahmann AJ, et al. Efficacy and Safety of Oral Semaglutide Compared with Placebo and Sitagliptin in Patients with Type 2 Diabetes. Lancet. 2019;394:175-184.
- Yokoyama Y, et al. Glucagon-like peptide-1 agonists for weight loss in adults with overweight or obesity. Cochrane Database Syst Rev. 2023;(4):CD013923.
- European Medicines Agency. Ozempic: EPAR – Product Information. 2024.
